|
Patent landscape, scope, and claims: |
United States Patent 9,364,435 (Nucleic Acid-Lipid Particles): Claim Scope, Coverage Boundaries, and US Patent Landscape
Executive summary: U.S. Patent 9,364,435 claims a composition and downstream methods built around a nucleic acid-lipid particle with a defined molar-ratio lipid architecture: (i) a cationic lipid (50–85 mol%), (ii) a non-cationic lipid (13–49.5 mol%), and (iii) an aggregation-inhibiting conjugated lipid (0.5–2 mol%). The claim set is broad on the cargo (siRNA/miRNA/antisense/mRNA/plasmid and mixtures) and broad on use (cell entry, in vivo delivery, and treatment with disease categories including viral infection, liver disease, and cancer). It is narrower on formulation execution via tight mol% ranges and specificity around PEG-lipid conjugate types and phospholipid/cholesterol composition.
What does US patent 9,364,435 claim and what is the composition scope for nucleic acid-lipid particles?
Short answer: The patent is centered on a lipid nanoparticle (LNP)-type nucleic acid carrier defined by three lipid components with specified molar ranges, plus PEG-lipid conjugates at 0.5–2 mol% for aggregation inhibition.
Core independent claim 1: lipid ratio architecture
Claim 1 recites a nucleic acid-lipid particle comprising:
- Nucleic acid (no structural sequence limitation in claim 1)
- Cationic lipid: 50 mol% to 85 mol% of total lipid
- Non-cationic lipid: 13 mol% to 49.5 mol% of total lipid
- Conjugated lipid inhibiting aggregation: 0.5 mol% to 2 mol% of total lipid
Key scope implications
- The claims cover a wide continuum of cationic-to-non-cationic blends, as long as total lipid mol% composition stays within the ranges.
- PEG or PEG-like aggregation inhibition is a formulation-critical limitation because dependent claims expressly identify it (claims 9–12), but claim 1 itself already requires a conjugated lipid that inhibits aggregation. In practice, design-arounds often test whether the “conjugated lipid” is truly “aggregation inhibiting” under the patent’s definition.
Dependent claims narrow the lipid identity
Dependent claims add specific “preferred embodiments” that can be used for infringement mapping and for freedom-to-operate (FTO) scoping.
Nucleic acid types (claim 2–3)
- Claim 2: nucleic acid comprises interfering RNA, mRNA, antisense oligonucleotide, ribozyme, plasmid, immunostimulatory oligonucleotide, or mixtures.
- Claim 3: interfering RNA includes siRNA, aiRNA, miRNA, or mixtures.
Cationic lipid narrower sub-range (claim 4)
- Cationic lipid: 50–65 mol%
Non-cationic lipid narrower set (claim 5–8)
- Claim 5: mixture of phospholipid and cholesterol (or derivative)
- Claim 6: phospholipid is DPPC, DSPC, or mixture
- Claim 7: phospholipid 3–15 mol%
- Claim 8: cholesterol (or derivative) 30–40 mol%
PEG-aggregation inhibitor specification (claim 9–12)
- Claim 9: conjugated lipid is a PEG-lipid conjugate
- Claim 10: PEG-lipid conjugate includes PEG-DAG or PEG-DAA, or mixtures
- Claim 11: PEG-DAA includes PEG-DMA or PEG-DSA, or mixtures
- Claim 12: conjugated lipid range is 1–2 mol% (subset of the 0.5–2 mol% in claim 1)
Encapsulation (claim 13)
- Nucleic acid is fully encapsulated.
Downstream claims extend to composition use
- Claim 14: pharmaceutical composition of claim 1 particle + carrier.
- Claim 15: method of introducing nucleic acid into cells by contacting cells with claim 1 particle.
- Claim 16: in vivo delivery to a mammal by administering claim 1 particle.
- Claim 17–20: treating a disease in mammal by administering a therapeutically effective amount; disease examples include viral infection (claim 18), liver disease (claim 19), and cancer (claim 20).
How broad are the claims across nucleic acid payloads (siRNA vs mRNA vs antisense) and what does that mean for infringement risk?
Short answer: The claims are payload-broad and generically cover most nucleic-acid modalities used in modern LNP platforms, so infringement risk hinges more on lipid composition and PEG/aggregation inhibitor than on RNA chemistry.
Claim payload breadth
- Claim 2 explicitly enumerates modalities: interfering RNA, mRNA, antisense, ribozyme, plasmid, immunostimulatory oligonucleotide.
- Claim 3 further enumerates interfering RNA subclasses: siRNA, aiRNA, miRNA.
Practical infringement reading
- A product using mRNA-LNP, siRNA-LNP, or antisense-LNP faces composition-level risk if the formulation falls within the lipid mol% architecture and includes the claimed aggregation-inhibiting conjugated lipid at the stated levels.
- If the therapeutic payload is outside these categories, claim 2 could weaken; but claim 1 still requires a “nucleic acid” generally, which is typically read broadly in patent litigation depending on the specification.
Encapsulation limitation (claim 13) is a key carve-point
- If a competitor’s particle is not “fully encapsulated” (for example, nucleic acid loosely associated or partially exposed), claim 13 may not apply.
- But claim 1 does not expressly require “fully encapsulated,” so encap status is mainly relevant to dependent-claim coverage.
What lipid-design constraints create the main “claim boundaries” for nucleic acid-lipid particles under US 9,364,435?
Short answer: The strongest practical boundaries are the mol% ranges for the cationic lipid, non-cationic lipid, and conjugated aggregation inhibitor, plus the PEG-lipid identity in dependent claims.
Composition constraints (claim 1)
- Cationic lipid: 50–85 mol%
- Non-cationic lipid: 13–49.5 mol%
- Aggregation-inhibiting conjugated lipid: 0.5–2 mol%
Interpretive risk note for product developers
- If a product’s formulation uses a different ratio outside these windows, claim 1 can fall away.
- If the formulation fits within the windows but uses a different “conjugated lipid” than PEG-lipid (or uses PEG outside the claimed range), dependent claims 9–12 become harder to assert, but claim 1 still requires a conjugated aggregation-inhibitor unless the non-PEG component cannot meet the “inhibits aggregation” functional limitation.
Sub-ranges and preferred embodiments
- Cationic lipid 50–65 mol% (claim 4) narrows one embodiment but does not retract claim 1’s wider 50–85 range.
- Non-cationic specificity: phospholipid = DPPC/DSPC and phospholipid 3–15 mol% plus cholesterol 30–40 mol% (claims 6–8) is a formulation “fingerprint.” Many LNPs use DSPC/DPPC and cholesterol, so this can align with common market formulations, raising the need to verify exact mol%.
PEG-lipid range tightness
- Claim 1: 0.5–2 mol%
- Claim 12: 1–2 mol%
- Dependent claim 11/10: specific PEG-lipid families PEG-DAG and PEG-DAA, including PEG-DMA/PEG-DSA.
This creates a two-level risk:
- Claim 1 risk if the product has any conjugated aggregation inhibitor meeting the functional limitation within 0.5–2 mol%.
- Higher claim 9–12 risk if the product uses PEG-DAG/PEG-DMA/PEG-DSA at 1–2 mol% and includes phospholipid/cholesterol compositions matching dependent claims 5–8.
Which downstream uses are covered: cell entry, in vivo delivery, and therapeutic treatment for viral infection, liver disease, or cancer?
Short answer: The patent adds broad method-of-use coverage tied to administering the claimed particle. Disease examples are embedded but the claim is not limited to a single indication.
Method claims
- Claim 15: contacting cells with the particle to introduce nucleic acid.
- Claim 16: in vivo delivery by administering to a mammalian subject.
- Claim 17: treating a disease/disorder in a mammalian subject by administering a therapeutically effective amount.
- Claim 18: viral infection.
- Claim 19: liver disease/disorder.
- Claim 20: cancer.
Infringement pattern
- If a device is “use” infringement, the composition plus the act of administration matter.
- For commercial products, method claims often become relevant in parallel with composition claims, especially where label indications match claim 17’s disease categories.
What patent landscape surrounds US 9,364,435 for nucleic acid-lipid nanoparticles: typical claim overlaps and likely competitors?
Short answer: Without the patent’s prosecution history, specification disclosure, assignee, priority data, and citation graph, the landscape can only be mapped structurally to common LNP IP clusters: PEG-lipid aggregation control, cationic/non-cationic molar ratio design, and delivery into liver/cancer/viral disease indications.
Most likely technical overlap clusters
- Lipid nanoparticle composition claims
- Defined mol% for cationic lipid and helper lipid (phospholipid + cholesterol)
- Aggregation inhibitor PEG-lipid identity and loading
- PEG-lipid architecture claims
- PEG-lipid conjugate classes (DAG vs DAA)
- PEG-lipid mol% and chain architecture impacting aggregation and biodistribution
- Payload-agnostic nucleic acid LNP claims
- siRNA, mRNA, antisense, immunostimulatory oligos
- Method-of-use claims
- Viral infection, liver delivery, cancer gene silencing/expression control
How to read “scope fights” for competitors
- If a competitor uses a different aggregation inhibitor than PEG-lipid, it may avoid dependent claims but still face claim 1’s “conjugated lipid that inhibits aggregation” functional limitation.
- If a competitor uses different cationic/non-cationic mol% ratios, it can design around claim 1’s numerical windows.
- If a competitor changes encapsulation behavior, it can reduce dependent claim 13 risk but does not automatically avoid claim 1 and claim 15–20.
How strong is the patent estate for US 9,364,435 based on claim structure (not on external citations)?
Short answer: The claim structure is strong for coverage because it combines (i) a numerical formulation definition and (ii) broad payload and use coverage. It is weaker only where competitors can move outside mol% windows or replace PEG/aggregation inhibitor.
Strength drivers
- Numerical ranges create measurable infringement triggers.
- Payload breadth reduces “payload escape.”
- Method claims create leverage in product launch and label alignment scenarios.
Primary vulnerability vectors
- Formulation “ratio” escape: changing mol% outside the windows.
- Aggregation inhibitor escape: using a conjugated lipid that does not meet the “inhibits aggregation” functional limitation or falls outside the claimed mol% range.
- Encapsulation escape (limited): challenging “fully encapsulated” if dependent claim 13 is asserted.
What generic or biosimilar-style launch risks exist for nucleic acid-lipid particles under this patent?
Short answer: “Generic” for LNPs is usually evaluated as a composition equivalence and functional/structural similarity problem rather than a single active ingredient bioequivalence. For US 9,364,435, risk concentrates on whether an entrant’s LNP hits the mol% architecture and aggregation inhibitor limitations.
Launch risk map
- High risk: entrant uses cationic lipid at 50–85 mol%, helper lipid at 13–49.5 mol%, and PEG-lipid (PEG-DAG or PEG-DAA, including PEG-DMA/PEG-DSA) at 0.5–2 mol% or 1–2 mol%.
- Moderate risk: entrant stays within mol% for cationic/non-cationic but changes the aggregation inhibitor class or loading.
- Lower risk: entrant shifts mol% outside at least one window and/or eliminates PEG-lipid at the claimed levels.
What formulations are explicitly protected (PEG-DAG, PEG-DAA, PEG-DMA, PEG-DSA; DPPC/DSPC; cholesterol 30–40 mol%)?
Short answer: Dependent claims explicitly protect a set of “assembly recipes” combining common helper lipids and PEG-lipid subtypes.
Explicit formulation elements by claim
- PEG-lipid conjugate types (claims 9–11)
- PEG-DAG
- PEG-DAA including PEG-DMA and PEG-DSA
- PEG-lipid loading (claim 12)
- 1–2 mol% (subset of 0.5–2 mol% in claim 1)
- Non-cationic lipid composition (claims 5–8)
- Phospholipid + cholesterol/derivative
- Phospholipid: DPPC and/or DSPC
- Phospholipid: 3–15 mol%
- Cholesterol/derivative: 30–40 mol%
This combination is typical of several LNP platforms, which increases the need for molecule-level and mol%-level formulation comparison.
How do the claim ranges interact, and what mol% “feasibility” constraints do they create?
Short answer: The windows overlap and allow multiple recipes, but the conjugated aggregation inhibitor is constrained to a narrow percentage band that becomes a major degrees-of-freedom limiter.
Feasibility envelope (claim 1)
Let total lipid = 100 mol%.
- Conjugated lipid: 0.5–2 mol%
- Cationic lipid: 50–85 mol%
- Non-cationic lipid: 13–49.5 mol%
Because the three components sum to 100, the chosen band for one component forces others closer to edges. For example:
- If conjugated lipid is near 2 mol%, the remaining 98 mol% must be split between cationic (50–85) and non-cationic (13–49.5).
- If conjugated lipid is near 0.5 mol%, the remaining 99.5 mol% similarly must satisfy the other two bounds.
In practice, product formulators adjust PEG-lipid loading and cationic helper ratios; those adjustments can be directly tested against claim 1’s numeric windows.
Key Takeaways
- US 9,364,435 claims an LNP-like nucleic acid particle defined by numerical mol% composition: cationic lipid 50–85, non-cationic lipid 13–49.5, aggregation-inhibiting conjugated lipid 0.5–2.
- The patent is payload-broad (siRNA/aiRNA/miRNA, mRNA, antisense, ribozyme, plasmid, immunostimulatory oligos) and includes broad method-of-use claims for cell entry, in vivo delivery, and treating disease including viral infection, liver disease, and cancer.
- Dependent claims add strong formulation fingerprints: PEG-lipid identities (PEG-DAG/PEG-DAA including PEG-DMA/PEG-DSA), PEG loading 1–2 mol%, and helper lipid composition (DPPC/DSPC, phospholipid 3–15 mol%, cholesterol 30–40 mol%).
- For design-around strategies, the decisive levers are (i) moving outside mol% windows and (ii) altering the aggregation inhibitor class/loading so it no longer satisfies the conjugated lipid limitation.
FAQs
-
Does US 9,364,435 cover mRNA delivery if the nucleic acid is fully encapsulated?
Yes. Claim 2 explicitly includes mRNA, and claim 13 adds “fully encapsulated” as a dependent limitation.
-
What is the most important numerical limitation to avoid infringement under claim 1?
The mol% ranges for the cationic lipid (50–85), non-cationic lipid (13–49.5), and aggregation-inhibiting conjugated lipid (0.5–2).
-
Are PEG-DAG and PEG-DAA protected under dependent claims?
Yes. PEG-DAG and PEG-DAA (including PEG-DMA and PEG-DSA) are identified as PEG-lipid conjugate types in claims 10–11.
-
If an entrant uses DPPC or DSPC and cholesterol, does that automatically infringe?
No. Infringement requires matching the overall claim architecture, including the cationic/non-cationic/PEG-conjugate mol% structure and the required conjugated lipid role.
-
Do the method claims require a specific disease indication wording on a label?
The claims are written to treating a disease/disorder by administering a therapeutically effective amount, with examples including viral infection, liver disease, and cancer. Practical enforcement typically maps to the therapeutic use.
References (APA)
- United States Patent 9,364,435.
More… ↓
⤷ Start Trial
|
